Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: A pediatric oncology group study

E. G. Douglass*, M. Reynolds, M. Finegold, A. B. Cantor, A. Glicksman

*Corresponding author for this work

Research output: Contribution to journalArticle

141 Scopus citations

Abstract

Purpose: To estimate the disease-free survival rate in children with grossly resected hepatoblastoma treated with cisplatin, vincristine, and fluorouracil (CDDP/VCR/ FU) and to assess the disease-response rate and disease-free survival (DPS) rate in children with unresectable or metastatic tumors treated with this combination. Patients and Methods: Sixty assessable patients with hepatoblastoma received therapy with five (stage I and II) to seven (stage III and IV) courses of CDDP (90 mg/ m2), day 1, and VCR (1.5 mg/m2), and FU (600 mg/m2), day 3. Results: Nineteen of 21 patients with stage I or II disease survive free of disease (actuarial survival, 90% at 5 years). Twenty-four of 31 patients with stage III disease achieved a complete remission (CR) after chemotherapy and surgical excision; actuarial DPS at 4 years is 67%. Only one of eight patients with stage IV disease achieved a remission and survives. Conclusion: Relatively brief exposure to chemotherapy with CDDP/VCR/FU provided excellent disease control to patients with grossly resected tumors. In patients with initially unresectable disease, this therapy provides a response rate and DPS rate comparable to regimens that contain doxorubicin (DOX).

Original languageEnglish (US)
Pages (from-to)96-99
Number of pages4
JournalJournal of Clinical Oncology
Volume11
Issue number1
DOIs
StatePublished - Jan 1 1993

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: A pediatric oncology group study'. Together they form a unique fingerprint.

  • Cite this